New clinical trials for cancer patients at Sarah Cannon Research Institute | Dr Tobias-Hendrik Arkenau at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, explains that the development of immunotherapies for a variety of cancer types and specific cancer proteins is a very active area of research at Sarah Cannon Research Institute.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews